Talk:Olaparib

Question
Does it inhibit just PARP1 or other PARP enzymes ? Rod57 (talk) 11:43, 22 October 2009 (UTC)

Exaggerated coverage
The Journal of the National Cancer Institute gave olaparib as an example of exaggerated coverage in the news media. Promoting Healthy Skepticism In The News: Helping Journalists Get It Right

Try to keep out some of the more hysterical claims. --Nbauman (talk) 01:56, 23 November 2009 (UTC)

FDA approved yesterday
An FDA news release announces:


 * FDA approves Lynparza to treat advanced ovarian cancer
 * First LDT companion diagnostic test also approved to identify appropriate patients

Hope this is useful. --Hordaland (talk) 02:08, 20 December 2014 (UTC)

How many people have taken this?
It would be helpful to get some statistical estimates of how many people have taken this medication. That would help me, as a consumer, evaluate its effectiveness and safety. I think it's a fairly rare medication, but I'm not sure. — Preceding unsigned comment added by Skysong263 (talk • contribs) 15:16, 8 May 2018 (UTC)

Dangling References
Reference #6 (to: http://www.emea.europa.eu/pdfs/human/comp/opinion/51078707en.pdf ) referes to non-existent target.